Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease

JAMA Internal Medicine

Volumn 173, Issue 13, 2013, Pages 1175-1184

  Gershon, Andrea ^a,b,c,d   Croxford, Ruth ^a   Calzavara, Andrew ^a   To, Teresa ^a,c,d   Stanbrook, Matthew B ^d   Upshur, Ross ^a,b,d   Stukel, Thér̀ese A ^a,d  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIGOXIN; DIPYRIDAMOLE; DIURETIC AGENT; NITRITE; NONSTEROID ANTIINFLAMMATORY AGENT; SPIRONOLACTONE;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DRUG SAFETY; EMERGENCY WARD; HEART ARRHYTHMIA; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POPULATION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

ADMINISTRATION, INHALATION; AGED; BRONCHODILATOR AGENTS; CASE-CONTROL STUDIES; CHOLINERGIC ANTAGONISTS; COHORT STUDIES; FEMALE; HEART FAILURE; HUMANS; MALE; MONITORING, PHYSIOLOGIC; ONTARIO; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME;

EID: 84879999170     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.1016     Document Type: Article

References (30)

1. Gershon AS, Warner L, Cascagnette P, Victor JC, To T. Lifetime risk of developing chronic obstructive pulmonary disease (COPD): a longitudinal population study. Lancet. 2011;378(9795):991-996.
2. Kochanek KD, Xu J, Murphy BS, Minino AM, Kung H. Deaths: preliminary data for 2009. Natl Vital Stat Rep. 2011;59(4):1-51.
3. Benady S. The Human and Economic Burden of COPD: A Leading Cause of Hospital Admission in Canada. Ottawa, ON: Canadian Thoracic Society; 2010.
4. Calverley PM, Anderson JA, Celli B, et al; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789. (Pubitemid 46294610)
5. Tashkin DP, Celli B, Senn S, et al UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-1554.
6. Qaseem A, Wilt TJ, Weinberger SE, et al American College of Physicians; American College of Chest Physicians; American Thoracic Society; European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155(3):179-191.
7. Singh S, Loke YK, Enright P, Furberg CD. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications [published online July 4, 2012]. Thorax. doi:10.1136/thoraxjnl-2011-201275.
8. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: ameta-analysis. Chest. 2004;125(6):2309-2321. (Pubitemid 38796452)
9. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12):1439-1450.
10. Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ. 2011;342:d3215. doi:10.1136/bmj.d3215.
11. Au DH, Curtis JR, Every NR, McDonell MB, Fihn SD. Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. Chest. 2002;121(3):846-851. (Pubitemid 34251453)
12. Suissa S, Ernst P, Vandemheen KL, Aaron SD. Methodological issues in therapeutic trials of COPD. Eur Respir J. 2008;31(5):927-933.
13. Jara M, Lanes SF, Wentworth C III, May C, Kesten S. Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. Drug Saf. 2007;30(12):1151-1160. (Pubitemid 350172856)
14. Jara M, Wentworth C III, Lanes S. A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD. BMJ. 2012;2(3):e000841. doi:10.1136/bmjopen-2012-000841.
15. Gershon A, Croxford R, To T, et al. Comparison of inhaled long-acting β-agonist and anticholinergic effectiveness in older patients with chronic obstructive pulmonary disease: a cohort study. Ann Intern Med. 2011;154(9):583-592.
16. Vogelmeier C, Hederer B, Glaab T, et al POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093-1103.
17. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying individuals with physician diagnosed COPD in health administrative databases. COPD. 2009;6(5):388-394.
18. Roger VL, Go AS, Lloyd-Jones DM, et al American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2-e220.
19. PCCF+ Version 4D User's Guide (Geocodes/PCCF): Automated Geographic Coding Based on the Statistics Canada Postal Code Conversion Files, Including Postal Codes to December 2003 [computer program]. Ottawa, ON: Statistics Canada; 2004.
20. The Johns Hopkins University ACG Case-Mix System [computer program]. Version 8.0. Baltimore, MD: John Hopkins University; 2006.
21. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Comm Statist Simulation Comput. 2009;38(6):1228-1234.
22. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 2007;26(4):734-753. (Pubitemid 46206593)
23. D'Agostino RB Jr. Propensity scoremethods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265-2281.
24. Allison PD. Logistic Regression Using SAS: Theory and Application. Cary, NC: SAS Institute Inc; 1999.
25. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15(5):291-303. (Pubitemid 43797117)
26. Lee TA, Wilke C, Joo M, et al. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2009;169(15):1403-1410.
27. Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med. 2008;149(6):380-390.
28. Au DH, Udris EM, Curtis JR, McDonell MB, Fihn SD; ACQUIP Investigators. Association between chronic heart failure and inhaled β-2-adrenoceptor agonists. Am Heart J. 2004;148(5):915-920.
29. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010;137(1):20-30.
30. US Food and Drug Administration. Early Communication About an Ongoing Safety Review of Tiotropium. Washington, DC: US Dept of Health & Human Services; 2008. Metabolism, and Diabetes